Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 209

Similar articles for PubMed (Select 19233218)

1.

alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment.

Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD.

Neuropharmacology. 2009 May-Jun;56(6-7):1001-9. doi: 10.1016/j.neuropharm.2009.02.003. Epub 2009 Feb 21.

PMID:
19233218
2.

α7 nicotinic receptor agonism mitigates phencyclidine-induced changes in synaptophysin and Arc gene expression in the mouse prefrontal cortex.

Thomsen MS, Hansen HH, Mikkelsen JD.

Neurochem Int. 2010 Dec;57(7):756-61. doi: 10.1016/j.neuint.2010.08.013. Epub 2010 Sep 15.

PMID:
20817066
3.

Effects of repeated treatment of phencyclidine on cognition and gene expression in C57BL/6 mice.

Beraki S, Diaz-Heijtz R, Tai F, Ogren SO.

Int J Neuropsychopharmacol. 2009 Mar;12(2):243-55. doi: 10.1017/S1461145708009152. Epub 2008 Aug 7.

PMID:
18684341
4.

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711.

Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M.

Biol Psychiatry. 2008 Jan 1;63(1):92-7. Epub 2007 Jun 28.

PMID:
17601496
5.

The alpha7 nicotinic receptor agonist SSR180711 increases activity regulated cytoskeleton protein (Arc) gene expression in the prefrontal cortex of the rat.

Kristensen SE, Thomsen MS, Hansen HH, Timmermann DB, Hay-Schmidt A, Mikkelsen JD.

Neurosci Lett. 2007 May 17;418(2):154-8. Epub 2007 Mar 12.

PMID:
17379406
6.
7.

Opposite effect of phencyclidine on activity-regulated cytoskeleton-associated protein (Arc) in juvenile and adult limbic rat brain regions.

Thomsen MS, Hansen HH, Mikkelsen JD.

Neurochem Int. 2010 Jan;56(2):270-5. doi: 10.1016/j.neuint.2009.10.011. Epub 2009 Nov 6.

PMID:
19897002
8.
9.
11.

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats.

Campbell UC, Lalwani K, Hernandez L, Kinney GG, Conn PJ, Bristow LJ.

Psychopharmacology (Berl). 2004 Sep;175(3):310-8.

PMID:
15024550
12.

Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain.

Christensen DZ, Mikkelsen JD, Hansen HH, Thomsen MS.

J Neurochem. 2010 Aug;114(4):1205-16. doi: 10.1111/j.1471-4159.2010.06845.x. Epub 2010 Jun 1.

PMID:
20533993
13.

The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat.

Thomsen MS, Mikkelsen JD, Timmermann DB, Peters D, Hay-Schmidt A, Martens H, Hansen HH.

Neuroscience. 2008 Jun 23;154(2):741-53. doi: 10.1016/j.neuroscience.2008.03.083. Epub 2008 Apr 16.

PMID:
18495359
14.

Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment.

Kjaerby C, Bundgaard C, Fejgin K, Kristiansen U, Dalby NO.

Neuropharmacology. 2013 Sep;72:157-68. doi: 10.1016/j.neuropharm.2013.04.041. Epub 2013 May 2.

PMID:
23643744
15.

The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.

Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.

J Pharmacol Exp Ther. 2007 May;321(2):716-25. Epub 2007 Feb 16.

16.

Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics.

Didriksen M, Skarsfeldt T, Arnt J.

Psychopharmacology (Berl). 2007 Aug;193(2):225-33. Epub 2007 Apr 4.

PMID:
17406859
17.

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):17-34. Epub 2006 Aug 23.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk